These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 15717014)

  • 1. Neurodegeneration and neuroprotection in Parkinson disease.
    Fahn S; Sulzer D
    NeuroRx; 2004 Jan; 1(1):139-54. PubMed ID: 15717014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?
    Barzilai A; Melamed E; Shirvan A
    Cell Mol Neurobiol; 2001 Jun; 21(3):215-35. PubMed ID: 11569535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
    Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
    Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop.
    Fahn S; Clarence-Smith KE; Chase TN
    Mov Disord; 1998 Sep; 13(5):759-67. PubMed ID: 9756143
    [No Abstract]   [Full Text] [Related]  

  • 8. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality.
    Marsden CD; Olanow CW
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S189-96. PubMed ID: 9749592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.
    Maasz G; Zrinyi Z; Reglodi D; Petrovics D; Rivnyak A; Kiss T; Jungling A; Tamas A; Pirger Z
    Dis Model Mech; 2017 Feb; 10(2):127-139. PubMed ID: 28067625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Where do we stand on neuroprotection? Where do we go from here?
    Shoulson I
    Mov Disord; 1998; 13 Suppl 1():46-8. PubMed ID: 9613718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the extranigral aspects of Parkinson disease.
    Lim SY; Fox SH; Lang AE
    Arch Neurol; 2009 Feb; 66(2):167-72. PubMed ID: 19204152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
    Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
    Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors which can play important role in pathogenesis of Parkinson disease].
    Koziorowski D; Jasztal J
    Neurol Neurochir Pol; 1999; 33(4):907-21. PubMed ID: 10612105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.